Examining cognitive changes in breast cancer survivors compared to healthy older adults
Cognitive Aging in Older Long-term Breast Cancer Survivors
This study looks at how memory and attention change over time in older breast cancer survivors compared to healthy older adults to see if there are any differences in their mental functions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 420 (estimated) |
| Ages | 60 Years to 80 Years |
| Sex | Female |
| Sponsor | Memorial Sloan Kettering Cancer Center Academic / other |
| Drugs / interventions | rituximab, chemotherapy, radiation, methotrexate, cyclophosphamide, Cytoxan |
| Locations | 7 sites (Basking Ridge, New Jersey and 6 other locations) |
| Trial ID | NCT06334354 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate how cognitive functions, such as memory and attention, change over time in breast cancer survivors aged 65-80 compared to healthy volunteers of the same age. Participants will undergo neurocognitive testing to assess differences in mental function between the two groups. The study will include assessments of cognitive performance and may involve genetic testing related to cognitive aging. By comparing these two populations, researchers hope to gain insights into the impact of breast cancer on cognitive health.
Who should consider this trial
Good fit: Ideal candidates for this study are female breast cancer survivors aged 65-80 who have no evidence of disease and are fluent in English.
Not a fit: Patients with active breast cancer or those who do not meet the age and health criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable information on cognitive aging in breast cancer survivors, potentially leading to targeted interventions to improve their quality of life.
How similar studies have performed: Other studies have explored cognitive changes in cancer survivors, suggesting that this approach may yield meaningful insights, although this specific comparison with healthy older adults is less common.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
All Participants:
* Per medical record and/or self-report, identifies as female
* Per medical record and/or self-report, currently age 60-80
* Per self-report, has access to a computer and internet connectivity
* Score of \<11 on Blessed Orientation-Memory-Concentration Test (BOMC)
* As per medical record or self-report, if currently taking psychoactive medications (including but not limited to antidepressants and anxiolytics), dose must have been stable at least two months prior to enrollment.
* English fluent (as per self-report, fluency of "well" or "very well", and having a reasonable comprehension of the study conversation in the opinion of the research staff)\*\*
Breast Cancer Survivors:
* Per medical record and/or self-report, history of stage 0-3 breast cancer diagnosed between 50-60 years of age
* Per medical record and/or self-report, no evidence of disease (NED)
Non-Cancer Controls:
* Per self-report, no history of breast cancer
* Language verification: For both survivors and controls, prior to enrollment, all will be asked the following two questions by a CRC to verify English fluency necessary for participation in the study:
1. How well do you speak English? (must respond "Well" or "Very well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused)
2. What is your preferred language for healthcare? (must respond English)
Exclusion Criteria:
All participants:
* As per medical record or self-report, diagnosis of neurodegenerative disorder that affects cognitive function (e.g. Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, Dementia, Seizure Disorders, etc.)
* As per medical record or self-report, history of stroke or head injury resulting in a structural lesion on neuropsych imaging, persistent cognitive difficulties impacting work or daily life, or required cognitive rehabilitation
* As per medical record or self-report, a diagnosis of a major Axis I psychiatric disorder including Schizophrenia Spectrum Disorder, substance use disorder, Bipolar Disorder or Schizotypal personality disorder. Schizophrenia Spectrum Disorders include Schizophrenia, Schizophreniform disorder, Schizoaffective disorder, Delusional disorder, Brief psychotic disorder, and Attenuated Psychotic Disorder.
* As per medical record or self-report, visual or auditory impairment that would preclude ability to complete the assessments (e.g. history of significant macular degeneration or being unable to correct hearing with hearing aids)
* As per medical record or self-report, use of methotrexate (Amethopterin, Rhematrex, Trexall) or rituximab (Rituxin) for rheumatoid arthritis, psoriasis or Crohn's disease, or cyclophosphamide (Cytoxan, Neosar) for lupus.
* As per medical record or self-report, participation in a conflicting (overlapping neurocognitive assessments) research study (i.e. MSK 18-294)
Breast Cancer Survivors:
* As per medical record or self-report, history of cancer recurrence
* As per medical record or self-report, any history of another cancer except nonmelanoma skin cancer or first breast cancer (a secondary breast cancer is exclusionary)
* As per medical record or self-report, breast cancer only treated with surgery
Non-Cancer Controls:
* As per medical record or self-report, history of treatment using radiation, chemotherapy, and/or Tamoxifen or Aromatase-inhibitors
* As per medical record or self-report, any history of cancer except non-melanoma skin cancer
Where this trial is running
Basking Ridge, New Jersey and 6 other locations
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Bergen (All Protocol Activities) — Montvale, New Jersey, United States (Recruiting)
- Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities) — Commack, New York, United States (Recruiting)
- Memorial Sloan Kettering Westchester (All Protocol Activities) — Harrison, New York, United States (Recruiting)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (Recruiting)
- Memorial Sloan Kettering Nassau (All Protocol Activities) — Uniondale, New York, United States (Recruiting)
Study contacts
- Principal investigator: James Root, PhD — Memorial Sloan Kettering Cancer Center
- Study coordinator: James Root, PhD
- Email: rootj@mskcc.org
- Phone: 646-888-0035
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.